Ofatumumab
E854986
anticancer drug
anti‑CD20 antibody
immunosuppressive agent
monoclonal antibody
multiple sclerosis drug
Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
Observed surface forms (2)
| Surface form | Occurrences |
|---|---|
| ofatumumab | 1 |
| ofatumumab (autoimmune indications) | 1 |
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anticancer drug
ⓘ
anti‑CD20 antibody ⓘ immunosuppressive agent ⓘ monoclonal antibody ⓘ multiple sclerosis drug ⓘ |
| bindsTo | B‑lymphocyte antigen CD20 NERFINISHED ⓘ |
| blackBoxWarning |
hepatitis B virus reactivation
ⓘ
progressive multifocal leukoencephalopathy ⓘ |
| commonAdverseEffect |
headache
ⓘ
injection‑related reaction ⓘ upper respiratory tract infection ⓘ |
| currentMarketingAuthorizationHolder | Novartis NERFINISHED ⓘ |
| developer |
Genmab
NERFINISHED
ⓘ
GlaxoSmithKline NERFINISHED ⓘ |
| FDAApprovalYear | 2009 ⓘ |
| FDAMSApprovalYear | 2020 ⓘ |
| hasATCCode |
L01FA08
ⓘ
L04AA44 ⓘ |
| hasCASNumber | 679818-59-8 ⓘ |
| hasGenericName | ofatumumab NERFINISHED ⓘ |
| hasMolecularTargetClass | B‑cell surface antigen ⓘ |
| hasTradeName |
Arzerra
NERFINISHED
ⓘ
Kesimpta NERFINISHED ⓘ |
| hasUNIID | 6GBX3K8J0S ⓘ |
| indication |
B‑cell chronic lymphocytic leukemia
ⓘ
active secondary progressive multiple sclerosis ⓘ fludarabine‑ and alemtuzumab‑refractory chronic lymphocytic leukemia ⓘ primary refractory chronic lymphocytic leukemia ⓘ refractory small lymphocytic lymphoma ⓘ relapsing forms of multiple sclerosis ⓘ relapsing‑remitting multiple sclerosis ⓘ |
| isApprovedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| isChimeric | false ⓘ |
| isFullyHuman | true ⓘ |
| isGlycoprotein | true ⓘ |
| isHumanized | false ⓘ |
| isProducedIn | mammalian cell culture ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| mechanismOfAction |
induces B‑cell apoptosis
ⓘ
induces B‑cell lysis via antibody‑dependent cell‑mediated cytotoxicity ⓘ induces B‑cell lysis via complement‑dependent cytotoxicity ⓘ |
| pharmacologicalClass |
B‑cell depleting agent
ⓘ
selective immunosuppressant ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| target | CD20 NERFINISHED ⓘ |
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
ofatumumab
this entity surface form:
ofatumumab (autoimmune indications)